VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 712 filers reported holding VANECK VECTORS ETF TR in Q4 2022. The put-call ratio across all filers is 0.51 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,590 | -5.9% | 4,470 | 0.0% | 0.06% | +1.8% |
| Q2 2023 | $134,592 | -6.9% | 4,470 | 0.0% | 0.06% | -11.3% |
| Q1 2023 | $144,605 | +12.9% | 4,470 | 0.0% | 0.06% | +12.7% |
| Q4 2022 | $128,110 | +18.6% | 4,470 | 0.0% | 0.06% | +10.0% |
| Q3 2022 | $108,000 | -11.5% | 4,470 | 0.0% | 0.05% | 0.0% |
| Q2 2022 | $122,000 | -28.7% | 4,470 | 0.0% | 0.05% | -16.7% |
| Q1 2022 | $171,000 | +19.6% | 4,470 | 0.0% | 0.06% | +30.4% |
| Q4 2021 | $143,000 | +8.3% | 4,470 | 0.0% | 0.05% | +7.0% |
| Q3 2021 | $132,000 | +8.2% | 4,470 | +24.3% | 0.04% | +4.9% |
| Q2 2021 | $122,000 | +54.4% | 3,595 | +64.9% | 0.04% | +46.4% |
| Q4 2020 | $79,000 | +19.7% | 2,180 | +29.8% | 0.03% | +3.7% |
| Q3 2020 | $66,000 | -29.0% | 1,680 | -33.6% | 0.03% | -32.5% |
| Q2 2020 | $93,000 | +102.2% | 2,530 | +27.8% | 0.04% | +81.8% |
| Q1 2020 | $46,000 | +206.7% | 1,980 | +296.0% | 0.02% | +340.0% |
| Q4 2019 | $15,000 | – | 500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $19,873,035 | 80.92% |
| New Harbor Financial Group, LLC | 1,680,752 | $45,229,033 | 14.96% |
| TORQ CAPITAL MANAGEMENT (HK) Ltd | 139,000 | $3,740,490 | 9.95% |
| Vanderbilt University | 1,360,540 | $36,612,131 | 9.45% |
| Eschler Asset Management LLP | 300,000 | $8,073,000 | 9.42% |
| New Harbor Financial Group, LLC | 1,027,300 | $27,644,643 | 9.15% |
| Guild Investment Management, Inc. | 139,333 | $3,749,454 | 6.28% |
| Monaco Asset Management SAM | 750,000 | $20,182,500 | 5.98% |
| STRATEGIC INVESTMENT MANAGEMENT, LLC | 132,460 | $3,867,832 | 4.74% |
| PCG Wealth Advisors, LLC | 264,614 | $7,120,782 | 4.67% |